Journal article
Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia
Typhoid vaccination is a public health priority in developing countries where young children are greatly affected by typhoid fever. Because present vaccines are not recommended for children younger than 2 years, the Novartis Vaccines Institute for Global Health developed a conjugate vaccine (Vi-CRM197) for infant immunisation. The study assesses the immunogenicity and safety of Vi-CRM197 in participants of various ages in endemic countries in south and southeast Asia.
Authors
Languages
- English
Publication year
2014
Journal
The Lancet Infectious Diseases
Volume
2
Type
Journal article
Categories
- Vaccines & delivery devices
Diseases
- Typhoid
Countries
- India
- Pakistan
- Philippines
Tags
- New vaccine introduction
WHO Regions
- Eastern Mediterranean Region
- South-East Asia Region
- Western Pacific Region